Actuate Therapeutics, Inc.ACTU

Actuate Therapeutics, Inc. is a clinical-stage oncology outfit betting its pipeline on elraglusib, a small-molecule candidate aimed at pancreatic cancer and Ewing sarcoma. The company’s latest quarterly filing makes one thing unmistakably clear: the science is still racing ahead of the cash. For the three months ended 31 March 2026, Actuate booked a $5.6 million net loss and an operating loss of $5.7 million, while burning $5.0 million of operating cash and ending the period with just $8.1 million in the bank. Shareholders’ equity sits at a slender $3.8 million, and the diluted loss per share is $0.24 on 23.5 million shares outstanding-meaning every quarter feels like a reverse equity raise dressed in lab coats.

Elraglusib’s first-in-class promise is real enough to have earned a podium spot at ASCO 2026, where Actuate presented posters touting biomarker and early clinical data in first-line metastatic pancreatic cancer. The FDA’s clearance of the IND for oral elraglusib in May 2026 added regulatory momentum, but the operating ledger hasn’t changed: no revenue, continued cash burn, and a pipeline that remains pre-commercial. The company’s own website frames elraglusib as a breakthrough, yet the balance sheet reads like a cautionary tale about the distance between conference-room theatre and cash-flow reality.

The latest 10-Q shows total assets of $8.9 million against liabilities of $5.1 million as of 31 March 2026, with research and development expense clocking in at $2.6 million for the quarter. The company’s cash and cash equivalents stood at $8.1 million, but the burn from operations tells the sharper story: $5.0 million used in the quarter, leaving little buffer for the next stage of trials. The filing also reminds readers that forward-looking statements are inherently risky, a polite way of saying that the clinical, regulatory, and commercial paths remain uncertain despite the glossy slide decks.

The company’s investor materials and clinical-trial pages trumpet ongoing studies and a pipeline spanning cancer and inflammatory diseases leading to fibrosis, but none of the evidence supplied shows revenue, approvals, or partnerships that would convert hope into cash. The SEC EDGAR filings and companyfacts JSON confirm the cash-burn math but do not add clinical endpoints, timelines, or revenue milestones. Until those appear in a future 10-Q or 8-K, the file remains a story of potential versus present bank balance.

For those watching the space, the key question is whether elraglusib’s compelling science can outrun the cash runway. The company’s own risk factors warn that the clinical path may change, and the balance sheet shows the runway is already short. Evidence that would meaningfully change the file includes a signed partnership, a regulatory milestone with revenue implications, or a clear path to monetisation-not merely more posters at the next oncology congress.